HAINAN POLY
GenericsHAINAN POLY is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Dermatology.
HAINAN POLY's Key Drugs
HAINAN POLY's core commercial portfolio centers on CISATRACURIUM BESYLATE PRESERVATIVE FREE, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.
HAINAN POLY's Recent FDA Approvals
HAINAN POLY secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
HAINAN POLY's Therapeutic Areas
HAINAN POLY's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HAINAN POLY's Top Competitors
HAINAN POLY's closest competitors by therapeutic-area and drug-target overlap include Pfizer, APOTHECON, and PAI HOLDINGS PHARM. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HAINAN POLY Pipeline Snapshot
Active clinical trials for HAINAN POLY across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CISATRACURIUM BESYLATE PRESERVATIVE FREE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-01-19
- Latest
- 2026-08-28
- Applications
- 33